Partly. Rare myocarditis can damage heart muscle.

Cardiomyopathy and myocarditis are different conditions. Myocarditis is inflammation of the heart muscle, and it is a recognised, rare side effect of mRNA COVID vaccines. Surveillance systems and large national cohort studies have not found that the vaccines increase cardiomyopathy more broadly. Most vaccine-associated myocarditis resolves, though researchers continue to follow patients for lasting effects. Infection with SARS-CoV-2 poses a larger risk to the heart than vaccination. Because a minority of myocarditis cases could in theory progress to cardiomyopathy, the wording matters. The evidence does not support a general causal link.

• mRNA COVID vaccines are linked to rare myocarditis and pericarditis, mainly in males aged about 12 to 30, usually within about a week of a dose.
• Most vaccine-related myocarditis cases are mild and recover. Some follow-up studies find minor heart MRI changes in a minority of patients, and long-term data are still being gathered.
• No large population studies show a raised rate of cardiomyopathy after vaccination.
• COVID-19 infection itself carries a higher risk of myocarditis and other heart complications than vaccination does.
• Myocarditis can sometimes lead to cardiomyopathy, so rare cases can't be ruled out, but a causal link to chronic cardiomyopathy hasn't been established.

The established rare adverse effect is myocarditis, not cardiomyopathy as a broad category. Myocarditis can damage heart muscle and occasionally lead to cardiomyopathy, but available evidence does not precisely establish the vaccine-attributable risk of chronic cardiomyopathy. A diagnosis occurring after vaccination does not by itself establish causation. Seek prompt medical attention for chest pain, shortness of breath, or palpitations after vaccination. ([cdc.gov](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html?utm_source=openai))

• A causal association between mRNA COVID-19 vaccines and rare myocarditis is established. ([cdc.gov](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html?utm_source=openai))
• Myocarditis is heart-muscle inflammation; cardiomyopathy is heart-muscle disease that impairs pumping. They are related but not interchangeable diagnoses. ([cdc.gov](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html?utm_source=openai))
• Vaccine-associated myocarditis occurs most frequently in adolescent and young adult males, usually within seven days after a second mRNA dose. ([cdc.gov](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html?utm_source=openai))
• One follow-up study identified dilated cardiomyopathy in one patient in its post-vaccination myocarditis group; this is not the risk among all vaccine recipients. ([jacc.org](https://www.jacc.org/doi/full/10.1016/j.jacc.2022.09.049?ftag=YHF4eb9d17&utm_source=openai))
• Most patients improve, but recovery is not universal and longer-term heart abnormalities can persist in some patients. ([cdc.gov](https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html?utm_source=openai))

1. cdc.gov
2. cdc.gov
3. cdc.gov
4. cdc.gov
5. archive.cdc.gov
6. archive.cdc.gov
7. cdc.gov
8. cdc.gov

Cardiomyopathy—a disease of the heart muscle that impairs its ability to pump blood—is not a recognized adverse effect of COVID-19 vaccines. Public concern often conflates cardiomyopathy with myocarditis, which is acute inflammation of the heart muscle. Health authorities and extensive safety databases tracking billions of administered doses have confirmed a rare link between mRNA vaccines and myocarditis or pericarditis, particularly in adolescent and young adult males. However, these cases are typically mild and transient, and population-level data show no increased risk of cardiomyopathy or persistent heart muscle dysfunction following vaccination.

• Large-scale global surveillance studies have found no causal association between COVID-19 vaccination and cardiomyopathy or chronic heart failure.
• COVID-19 mRNA vaccines are associated with a very rare risk of myocarditis (heart inflammation) and pericarditis, most often in young males after the second dose.
• Most vaccine-associated myocarditis cases are mild, temporary, and resolve quickly with conventional treatment.
• COVID-19 infection itself poses a substantially higher risk of myocarditis, cardiomyopathy, and long-term cardiac damage than vaccination.

Myocarditis and pericarditis are inflammatory conditions, distinct from cardiomyopathy, which is a chronic disorder of the heart muscle's structure and function. The causal link between mRNA vaccines and myocarditis/pericarditis is well supported by surveillance data and epidemiological studies, and myocarditis can in some patients lead to lasting heart muscle damage, so a connection to cardiomyopathy is biologically plausible in rare cases. However, the direct evidence that vaccination causes cardiomyopathy at the population level is thin, while the risk from COVID-19 infection itself is higher. That mix of a real but narrow risk makes 'partly' the honest answer.

• Multiple national surveillance systems (US CDC, EMA, and others) found a small increased risk of myocarditis and pericarditis after mRNA vaccination, concentrated in males aged about 12-29 after the second dose.
• Estimated rates are on the order of a few extra cases per 100,000 vaccinated young males — above background but still rare.
• Most reported cases were mild and resolved with rest and standard treatment, though long-term follow-up data are still limited.
• Large cohort and database studies (for example, studies using US and Israeli national data published 2021-2023) found a higher risk of myocarditis after SARS-CoV-2 infection than after vaccination.
• Cardiomyopathy cases after vaccination appear in individual case reports, but population studies have not established a clear causal link to cardiomyopathy as a distinct outcome.

Scientific evidence confirms that mRNA COVID-19 vaccines can rarely cause myocarditis, an inflammation of the heart muscle, particularly in young males after the second dose. This risk is well-documented and monitored globally. However, cardiomyopathy—a chronic condition where the heart muscle becomes weakened and enlarged—is not established as a direct consequence of COVID-19 vaccination. Studies show that while myocarditis can occur, it typically resolves and does not progress to cardiomyopathy. In contrast, COVID-19 infection itself poses a significantly higher risk for both myocarditis and cardiomyopathy. The evidence is strong that the vaccine does not cause cardiomyopathy, but the rare myocarditis risk is acknowledged.

• Myocarditis is a recognized but rare adverse event following mRNA COVID-19 vaccination, especially in adolescent and young adult males.
• The risk is highest after the second dose of mRNA vaccines (Pfizer-BioNTech or Moderna).
• Most cases of vaccine-associated myocarditis are mild and resolve with treatment.
• There is no robust evidence linking COVID-19 vaccines to cardiomyopathy (a chronic disease of the heart muscle).
• COVID-19 infection itself is a much stronger risk factor for myocarditis and cardiomyopathy than vaccination.

1. Myocarditis following COVID‐19 vaccine - PMC - NIH pmc.ncbi.nlm.nih.gov
2. Systematic Review: The Impact of COVID-19 Vaccination on Myocarditis Risk and Recovery - PMC pmc.ncbi.nlm.nih.gov
3. Stanford Medicine study shows why mRNA COVID-19 vaccine can cause myocarditis med.stanford.edu
4. Pfizer Shares Available Analyses of Myocarditis and ... pfizer.com
5. COVID-19 Vaccination-Induced Cardiomyopathy Requiring ... pmc.ncbi.nlm.nih.gov
6. Myocarditis With COVID-19 mRNA Vaccines | Circulation ahajournals.org
7. Evidence for Autoimmunity in the Pathogenesis of COVID-19-Induced Myocarditis - PMC pmc.ncbi.nlm.nih.gov
8. Cardiovascular Assessment up to One Year After COVID-19 Vaccine–Associated Myocarditis | Circulation ahajournals.org